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Abstract
Background: Small fiber neuropathy generally leads to considerable pain and autonomic symptoms. Gain-of-function
mutations in the SCN9A- gene, which codes for the Nav1.7 voltage-gated sodium channel, have been reported in small
fiber neuropathy, suggesting an underlying genetic basis in a subset of patients. Currently available sodium channel
blockers lack selectivity, leading to cardiac and central nervous system side effects. Lacosamide is an anticonvulsant,
which blocks Nav1.3, Nav1.7, and Nav1.8, and stabilizes channels in the slow-inactivation state. Since multiple Nav1.7
mutations in small fiber neuropathy showed impaired slow-inactivation, lacosamide might be effective.
Methods/design: The Lacosamide-Efficacy-‘N’-Safety in Small fiber neuropathy (LENSS) study is a randomized,
double-blind, placebo-controlled, crossover trial in patients with SCN9A-associated small fiber neuropathy, with the
primary objective to evaluate the efficacy of lacosamide versus placebo. Eligible patients (the aim is to recruit 25)
fulfilling the inclusion and exclusion criteria will be randomized to receive lacosamide (200 mg b.i.d.) or placebo during
the first double-blinded treatment period (8 weeks), which is preceded by a titration period (3 weeks). The first
treatment period will be followed by a tapering period (2 weeks). After a 2-week washout period, patients will
crossover to the alternate arm for the second period consisting of an equal titration phase, treatment period, and
tapering period. The primary efficacy endpoint will be the proportion of patients demonstrating a 1-point average pain
score reduction compared to baseline using the Pain Intensity Numerical Rating Scale. We assume a response rate of
approximately 60 % based on the criteria composed by the Initiative on Methods, Measurement, and Pain Assessment
in Clinical Trials (IMMPACT) group for measurement of pain. Patients withdrawing from the study will be considered
non- responders. Secondary outcomes will include changes in maximum pain score, the Small Fiber Neuropathy
Symptoms Inventory Questionnaire, sleep quality and the quality of life assessment, patients’ global impressions of
change, and safety and tolerability measurements. Sensitivity analyses will include assessing the proportion of patients
having ≥ 2 points average pain improvement compared to the baseline Pain Intensity Numerical Rating Scale scores.
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Discussion: This is the first study that will be evaluating the efficacy, safety, and tolerability of lacosamide versus
placebo in patients with SCN9A-associated small fiber neuropathy. The findings may increase the knowledge on
lacosamide as a potential treatment option in patients with painful neuropathies, considering the central role of
Nav1.7 in pain.
Trial registration: ClinicalTrials.gov, NCT01911975. Registered on 13 July 2013.
Keywords: Small fiber neuropathy, Painful neuropathy, SCN9A gene, Nav1.7, Lacosamide, Randomized controlled trial
Background
Neuropathic pain is described as “pain caused by a le-
sion or disease of the somatosensory system” [1]. The
prevalence of neuropathic pain in the general population
is approximately 7 to 10 % [2, 3]. Neuropathic pain is
one of the main symptoms of small fiber neuropathy
(SFN), a condition that affects the thinly myelinated Aδ-
fibers and the unmyelinated C-fibers. Pain in SFN is
mostly described as an itching, burning sensation, usu-
ally occurring in a length-dependent pattern, starting in
the feet and hands [4]. Body pain is a major contributor
to the reduction of quality of life in patients with SFN
[5]. In addition to the neuropathic pain, patients with
SFN may suffer from autonomic symptoms [6, 7].
Voltage-gated sodium channels have been described to
play an important role in neuropathic pain [8]. In ap-
proximately 15 % of patients with SFN, gain-of-function
mutations in the SCN9A-, SCN10A-, and SCN11A- gene
have been reported [9–12]. The SCN9A- gene codes for
the voltage-gated sodium channel Nav1.7, which is pre-
dominantly expressed in the small nociceptive and auto-
nomic neurons. In addition to being associated with
SFN, gain-of-function mutations in the SCN9A- gene
have been described in the following human pain disor-
ders: inherited erythromelalgia (IEM) and paroxysmal
extreme pain disorder (PEPD) [13, 14]. Gain-of-function
mutations of the SCN9A- gene were found in 28 % of
patients with SFN proven by skin biopsy [9]. In a larger
cohort (n = 393), the prevalence of SCN9A- gene muta-
tions in patients diagnosed with SFN based on an abnor-
mal skin biopsy and/or abnormal temperature threshold
testing was approximately 9 % [12]. Therefore, NaV1.7
appears to be an appropriate target for treatment of dif-
ferent human neuropathic pain conditions, including the
SCN9A-associated SFN.
Current treatments for pain in patients with SFN are
far from satisfactory [15]. Less than 50 % of patients
achieve a pain reduction of 50 % [16, 17]. This is pos-
sibly due to drugs acting on target sites for which no
strong evidence of pathogenicity exists. In addition,
commercially available sodium channel blockers are
not selective for NaV1.7, thereby frequently causing
intolerable side effects involving the heart and central
nervous system.
Lacosamide is a functionalized amino acid molecule
that selectively enhances the slow inactivation of
voltage-gated sodium channels and interacts with the
collapsin-response mediator protein-2 [18]. Lacosamide
differs from other sodium channel blockers because of
its unique mechanism of action. It inhibits the currents
of hyperexcitable neurons of the voltage-gated sodium
channels Nav1.3, Nav1.7, and Nav1.8 by targeting the
slow-inactivation state and sparing channels with normal
activity [19, 20]. In patients with SCN9A-associated SFN,
multiple mutations in the SCN9A- gene have shown an
impaired slow-inactivation [9], which might potentially
be considered a target for the mechanism of action of
lacosamide. Therefore, a positive effect on pain reduc-
tion in these patients might be expected.
To date, no studies with lacosamide have been per-
formed in patients with SFN. Some evidence exists of
lacosamide reducing neuropathic pain and being well
tolerated in patients with a painful diabetic neuropathy
[21, 22]. The same results were seen in one study with pa-
tients with fibromyalgia [23]. However, no robust under-
lying mechanism has been presented in these studies.
Methods/design
Objective
The primary objective of this study is to determine the
efficacy and safety of lacosamide versus placebo in pa-
tients with SCN9A-associated SFN.
Study design
The Lacosamide-Efficacy-‘N’-Safety in SFN (LENSS)
study is a randomized, placebo-controlled, double-blind,
crossover-design study (Fig. 1). The study consists of 2
periods. Before the first period, the screening and base-
line measurements takes place. Subjects ulfilling the in-
clusion and exclusion criteria are subsequently
randomized to receive lacosamide or placebo. The first
period starts with the first titration period of 3 weeks, in
which study the medication (lacosamide or equivalent
placebo) will be gradually increased. Subsequently, pa-
tients enter the first treatment period of 8 weeks. This
period is followed by a 2-week tapering period. After a
2-week washout period, the second period, which is exe-
cuted in the same manner as the first period, begins.
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Subjects cross over to the alternate arm and undergo the
second 3-week titration period, followed by the second
treatment period (8 weeks) and a tapering period
(2 weeks). In both treatment periods, subjects receive
lacosamide 200 mg b.i.d. or placebo. Patients are exam-
ined at the study outpatient site at the entry and at the
end of both treatment periods (maximum of eight site
visits). In addition, subjects are contacted and inter-
viewed in a standardized manner by phone every 2 weeks
to determine clinical condition and well-being, and col-
lect data on safety and side effects. A follow-up visit is
performed approximately 4 weeks after the last dose of
study medication.
The use of drugs such as lamotrigine, carbamazepine,
oxcarbazepine, mexiletine, amitriptyline, and topical an-
algesics (e.g., lidocaine patches, capsaicin patches, and
oral/injectable corticosteroids) that act on sodium chan-
nels is not allowed during the study period. Participants
using these drugs require a washout period of at least
five half-lives (90 days for capsaicin patches, which have
the longest elimination period of the prohibited medica-
tions) prior to the screening visit. Other pain medica-
tions can be continued provided the dose and frequency
of dosing have been stable over the previous 30 days
prior to screening and remains unchanged during the
study period. Additional medication is recorded.
Study medication
Each treatment phase is preceded by a titration phase.
The dose of lacosamide is increased weakly, starting with
50 mg b.i.d. in the first week, followed by 100 mg b.i.d.
in the second week, and concluding with 150 mg b.i.d.
in the third week. After these 3 weeks, the treatment
phase begins for 8 weeks. Based on previous studies and
on the dose-related side effects, a dose of 200 mg b.i.d.
(or equivalent placebo) has been chosen as the mainten-
ance dose [24]. The subjects start with the maintenance
dose (200 mg b.i.d.) at the first day of the treatment
phase; therefore, this dose is not included in the titration
phase. After the treatment phase, the tapering phase be-
gins, with study medication (lacosamide or placebo) dos-
age being reduced at once to 100 mg b.i.d. in the first
week of the tapering period and then to 50 mg b.i.d. in
the second week of the tapering period.
A convenient treatment period of 8 weeks was chosen
based on literature findings and assuming that a positive
effect of lacosamide should be seen within this period,
thereby limiting the burden for patients [23].
Participants
A total of 25 subjects with genetically proven SCN9A-
associated SFN are being recruited into the trial.
SCN9A mutations classified as certainly, probably, or
potentially pathogenic are eligible for inclusion [25].
Subjects are recruited at the Maastricht University
Medical Center (MUMC+), the Netherlands.
Informed consent is obtained from all participants be-
fore any study procedure (e.g., questionnaires or neuro-
logical examination) is performed.
Inclusion criteria
Subjects must fulfill the following inclusion criteria to be
eligible:






















































Fig. 1 Schematic diagram of study
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2. Presence of a clinical diagnosis of Small Fiber
Neuropathy (SFN), with at least two of the




 Diminished pain and/or temperature sensation
 Dry eyes or mouth
 Orthostatic dizziness
 Bowel disturbances (constipation, diarrhea, or
gastroparesis)
 Urinary disturbances
 Sweat changes (hyperhidrosis/hypohidrosis)
 Visual accommodation problems and/or blurred
vision
 Hot flashes/palpitations
 Impotence or diminished ejaculation or
lubrication
3. In addition to the clinical diagnosis of SFN,
presence of confirmed abnormality on intra-epidermal
nerve fiber density evaluation (IENFD) and/or
Quantitative Sensory Testing (QST) [6, 7] and a
mutation in the SCN9A- gene, confirmed by
sequencing. Where possible, in vitro confirmation
of the functionality of the mutation should have
been performed and documented as has been
demonstrated previously [6, 9].
4. Presence of pain due to SFN for at least 3 months
prior to screening and an average self-reported pain
score of at least 3 during this time.
5. If on analgesic medication, subject must have a
stable analgesic medication regimen for a minimum
of 30 days before the start of the study and should
continue with the same unchanged regimen
throughout the study.
6. Evidence of a personally signed and dated informed
consent document indicating that the subject (or a
legal representative) has been informed of all
pertinent aspects of the study.
7. Subjects who are willing and able to comply with
scheduled visits, treatment plan, laboratory tests,
and other study procedures.
Exclusion criteria
Subjects presenting with any of the following cannot be
included in the study:
1. Subjects with predominantly signs of large nerve fiber
involvement (muscle weakness, loss of vibration sense,
or hyporeflexia/areflexia), or clinically significant
abnormal nerve conduction studies (NCS)
2. History or presence of illnesses known to cause SFN
(excluding diabetes mellitus), including liver, kidney,
or thyroid dysfunction, monoclonal gammopathy,
connective tissue disorders, sarcoidosis, Sjögren
syndrome, amyloidosis, Fabry disease, celiac disease,
HIV, and neurotoxic drugs (e.g., chemotherapy)
3. Subjects with other severe pain conditions, which
may impair the self-assessment of pain due to SFN
4. Any condition possibly affecting drug intake and
absorption (e.g., difficulty in swallowing, gastrectomy
and/or bowel resection)
5. History of known alcohol, analgesic, or illicit drug
abuse within 12 months of screening
6. Subjects taking medications with potential effect on
sodium channel functions, including lamotrigine,
carbamazepine, oxcarbazepine, mexiletine,
amitriptyline, and topical analgesics (e.g., lidocaine
patches, capsaicin patches, and oral/injectable
corticosteroids). These medications are prohibited until
the end of the study period and require a washout
period of at least five half-lives (90 days for capsaicin
patches, which is the longest elimination period of the
prohibited medications) prior to the screening visit
7. Twelve-lead ECG demonstrating QTcF (Fridericia’s
correction) > 450 or a QRS interval > 120 msec at
screening. If the QTcF exceeds 450 msec or the QRS
exceeds 120 msec, the ECG should be repeated two
more times and the average of the three QTcF values
should be used to determine the subject’s eligibility.
8. Severe renal impairment (creatinine clearance ≤
30 mL/min).
9. Treatment with an investigational drug within
30 days (or as determined by the local requirement,
whichever is longer) or five half-lives preceding the
first dose of study medication.
10. Participation in other studies during the period of
current study participation or has surgery planned
during the course of the study.
11. Pregnant females, breastfeeding females, or females
of childbearing potential not using effective and
medically reliable contraception or not agreeing to
continue effective contraception for at least 28 days
after the last dose of the investigational product.
12. Other clinically significant or unstable, or severe
acute or chronic medical, or psychiatric/
psychological condition or laboratory abnormality
that may increase the risk associated with study
participation or investigational product
administration or may interfere with the
interpretation of study results and, in the judgment
of the Investigator, would make the subject
inappropriate for entry into this study.
13. In the case of incidental findings, the patient and
his/her treating physician will be informed and
asked to undertake action if necessary. If a patient
does not want to be informed about possible
incidental findings and does not want his treating
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physician to be informed, the patient cannot
participate in this study.
Randomization
After the screening period, the patients return to our center.
To ensure that eligible subjects are compliant, we will verify
that at least 5 of the last 7 days of the pain diary are com-
pleted. This is important because the pain diary of the
screening period is used as the baseline measurement of the
primary outcome. Randomization is performed using ALEA
data management. This software is provided by the Trans
European Network for Clinical Trials Services (http://
www.tenalea.com/). The randomization is computer- con-
trolled based on the electronic case report form that is used.
A blinded message is send to the investigator and an un-
blinded message is send to the pharmacy. Patients are strati-
fied based on the type of the SCN9A variant ((1) genetic
variant and (2) genetically and functionally confirmed) and
on the clinical diagnosis of SFN ((1) abnormal skin biopsy,
(2) abnormal temperature threshold testing, and (3) abnor-
mal skin biopsy and abnormal temperature threshold).
Blinding
The study is subject-blinded and investigator-blinded until
the end of the study. Blinding codes are only broken in
emergency situations for reasons of subject safety.
The lacosamide and the matching placebo are pro-
vided as 50 mg tablets for oral administration. Tablets
are provided in containers. Rescue medication (acet-
aminophen) is provided in its approved marketed prod-
uct dress. All medication dispensed to the subjects are
to be returned to the investigator and double-checked
by the monitor to assure study compliance.
Compliance
The following compliance calculation will be applied:
%Compliance ¼ number of tablets taken=number
of tablets expected to have taken
 100:
Subjects are coded as being a noncompliant if the per-
centage compliance according to the above formula
is less than 80 % or greater than 120 % study drug
compliance.
Efficacy measurements
The daily Pain Intensity Numerical Rating Scale (PI-
NRS) consists of an 11-point numerical scale ranging
from 0 to 10, where 0 represents no pain and 10 the
worst pain possible. The subjects are asked to complete
the PI-NRS twice daily, in the morning and evening,
preferably at fixed time points. In addition, the daily
sleep interference scale (DSIS) is completed every day
on awakening in the morning. The DSIS consists of an
11-point numerical scale ranging from 0 (pain does not
interfere with sleep) to 10 (pain completely interferes with
sleep) and is used to determine sleep quality. At each as-
sessment, the following additional questionnaires are
completed: the Neuropathic Pain Scale (NPS), Small Fiber
Neuropathy Symptom Inventory Questionnaire (SFN-
SIQ), Patient’s Global Impression of Change (PGIC), and
the generic Short Form (36) Health Survey (SF-36).
Outcome measurements
The chosen outcomes are largely based on the inter-
national criteria advised by the IMMPACT group for
measurement of pain [26].
Primary outcome
The primary efficacy endpoint is defined as the propor-
tion of patients demonstrating a 1-point average pain
score reduction compared to baseline using the PI-NRS.
A 1-point change on the PI-NRS is considered the mini-
mum clinically important difference (MCID) according
to the unified rule of ½ x standard deviation (SD) and rec-
ommendations given by the IMMPACT group [26, 27].
Secondary outcome
Secondary outcomes include changes seen in the max-
imum pain score on the PI-NRS, the NPS, DSIS, PGIC,
SFN-SIQ, SF-36, adverse events, laboratory safety tests
(e.g., hematology and clinical chemistry), blood pressure
(BP), pulse rate (PR), and electrocardiogram (ECG).
Sensitivity analyses include assessing the proportion of
patients having ≥ 2 points average pain improvement
compared to their baseline PI-NRS scores.
Data management
An electronic case report file (eCRF) is used for each patient
to collect all data. To host the eCRF, MACRO electronic
data capture is used, powered by InferMed Ltd, London,
UK. It has been designed to support compliance with the
requirements of relevant regulatory bodies including Inter-
national Council for Harmonisation (ICH) Good Clinical
Practice (www.infermed.com). Assessments start at the
screening visit. In addition, assessments at site visits and by
phone are performed according to the scheme presented in
Fig. 1 and include a standardized interview to determine
the patient’s clinical condition and well-being, assess the
various questionnaires, determine compliance, assess la-
boratory results, and at predefined moments, perform
ECG. During each contact (visit or by phone), adverse
events, and concomitant medication are discussed. At
each visit, the diary and the remaining medications are
collected. A summary of the assessments made during
visits and telephone calls is provided in Table 1.
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Privacy of the patients is guaranteed; stored data
and materials are only identifiable to the person by a
sequentially assigned subject number. The handling
of personal data complies with the Dutch Personal
Data Protection Act (De Wet Bescherming Persoons-
gegevens, WBP). The SPIRIT checklist and figure for
this study protocol are shown in Additional files 1
and 2.







































Physical Examination (Full) X
Physical Examination (Brief) X X X X X X
Weight and Height X
Safety Laboratory Testsc X X X X X X
FSHd X
HbA1c blood teste X
12-lead ECG X X X X X X
BP (supine and standing) and PR X X X X X X
Daily Pain Diary (PI-NRS)f X X
Daily Sleep Interference Scale (DSIS)g X X
Neuropathic Pain Scale (NPS) X X X X X X X X X X X X X
SFN-SIQ Questionnaire X X X X X X X X X X X X X
Patient Global Impression of Change X X X X X X X X X X X X
SF-36 X X X X
Adverse Event Monitoringh X X
Concomitant Medicationh X X
Dispense Study Medicationi X X X X X X
Retrieve Study Medication dispensed
at previous study visit
X X X X X X
Dispense Rescue Medication X X X X X X
Retrieve Rescue Medication
dispensed at previous study visit
X X X X X X
Dispense and instruct on Daily Pain
Diaries
X
Retrieve Daily Pain Diary X X X X X X X X
Study medication compliance check X X X X X X
BP; blood pressure, ECG; electrocardiogram, FSH; follicle-stimulating hormone, HbA1c; hemoglobin A1c, NPS; neuropathic pain scale, PI-NRS; pain intensity
numerical rating scale, PR; pulse rate, SFN-SIQ; small fiber neuropathy symptom inventory questionnaire, T; telephone call, V; visit, SF-36; short form 36
a. Visit/study activity window can be ± 2 days
b. Subjects will be randomized provided they fulfill study selection criteria
c. Safety laboratory tests include hematology and clinical chemistry
d. Females who are 45-60 years of age who are amenorrheic for at least 1 year
e. HbA1c test to be performed in subjects with diabetes and at investigator’s discretion for subjects who do not have a clinical diagnosis of diabetes but present
with hyperglycemia on safety lab tests
f. Daily Pain Diary (PI-NRS) to be completed by subject twice daily (morning and evening pain scores) and reviewed by study personnel at scheduled clinic visits
g. Daily Sleep Interference Scale (DSIS) to be completed by subject once daily on waking starting morning after Screening Visit (V1)
h. Adverse events and concomitant medication will be monitored during the entire study
I. Full dosing instructions will be provided and the first dose of study medication will be taken on the evening of the SECOND study visit (V2)
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Safety reporting
Adverse events are recorded and monitored. The princi-
pal investigator is to be informed immediately in case of
any serious adverse event (SAE). Every SAE is reported
to the Ethics Committee. Suspected unexpected serious
adverse reactions (SUSAR) are also reported. Further-
more, all SUSARs are expedited to the competent au-
thorities in other Member States, according to the
requirements of the Member States.
Statistical analysis
Sample size
A 1-point change on the average PI-NRS compared to
baseline is considered as the MCID [26, 27]. We assume
a response rate of approximately 20 % in the placebo-
treated group, based on a meta-analysis of the placebo
effect in pain studies in which the effect varied from 7-
37 %, with a 50 % pain reduction in 16 %. In the
lacosamide-treated group, we assume a response rate of
approximately 60 % based on the IMMPACT criteria in
which the clinical relevant pain reduction may be less
than 50 %. Fixing a two-sided alpha at 5 %, a sample size
of 22 patients is required per treatment group to show
efficacy with 80 % power between the two groups (chi-
square test). Assuming a dropout rate of approximately
10 % (two to three patients), a total of 25 subjects will
be needed per treatment group (in a parallel study). Since
the number of patients with SCN9A-associated SFN is
limited, a crossover design was chosen to fulfill sample
size requirements with the inclusion of 25 subjects.
Type of analysis
The analyses are performed on the intention-to-treat
(ITT) population, defined as all patients who received at
least one dose of randomized study medication and had at
least one post-baseline assessment. Patients withdrawing
from the study are considered as nonresponders. The
comparison of the proportion of patients in both groups
(lacosamide versus placebo) reaching the predefined cut-
off is estimated using Kaplan-Meijer serial time series
graphs with a log-rank test.
For secondary efficacy endpoints, the treatment differ-
ences for change from baseline in selected outcome
measures, according to the predefined inquiries, are ana-
lyzed using nonparametric tests. The statistical tests
used depend on the type of data. Analyses of safety pa-
rameters are performed on the safety set (SS), which in-
cludes all randomized patients who took at least one
dose of trial medication. Individual missing data are
assigned using a last observation carried forward ap-
proach. Other missing-data treatment methods are per-
formed (for example single and multiple imputation) to
test which of these methods is the best according to sen-
sitivity analyses.
Discussion
In this study, the efficacy, safety, and tolerability of lacosa-
mide in patients with pain due to SCN9A-associated SFN
are studied. Despite earlier studies performed with lacosa-
mide in painful conditions, no study to date has been done
in patients with SCN9A-associated SFN. This is interesting
because most of them harbor an electrophysiological
mechanism of pain induction through impaired slow-
inactivation of the voltage-gated sodium channel NaV1.7
[28], which might be a potential target for lacosamide, tak-
ing into account its unique mechanism of targeting the
slow-inactivation [19]. Therefore, a positive effect on pain
reduction in these patients might be expected.
With lacosamide, we hope to find a new treatment op-
tion for the excruciating pain often reported by patients
with SFN. This is the first pilot study that aims to show
the efficacy, tolerability, and safety of lacosamide in this
specific cohort of patients with SCN9A-associated SFN.
If lacosamide proves to be effective in SFN patients with
a Nav1.7 mutation, this might be a viable option for pa-
tients with painful neuropathies or with neuropathic pain
in general, considering the central role of Nav1.7 in pain.
The first results of the study are expected in mid-2017.
Trial status
Participant recruitment for this trial is ongoing. Recruit-
ment began in November 2014 and is expected to end
mid-2016.
Additional files
Additional file 1: Checklist SPIRIT. (DOC 121 kb)
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